Collectively, these results support the finding that PCK1 deficiency alleviates SAM biosynthesis and H3K9me3 modification in S100A11, thereby promoting aberrant PI3K/AKT activation and tumor progression in human primary HCC. Here, S100A11 is linked to hepatocellular carcinoma.